Healthcare · Medical - Devices
Price
$18.76
Market Cap
$1.5B
Employees
4,396
Beta
1.25
Avg Volume
976,125
CEO
Mojdeh Poul
Business Description
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
Business History
Price Overview
Last updated: Jun 27, 2026 9:04am (just now)$18.76
+0.66 (+3.65%)
Day Range
$18.00 – $18.90
52-Week Range
$8.70 – $18.90
50-Day MA
$14.62
200-Day MA
$12.84
Volume
1,839,169.00
Analyst Price Targets
Low
$12.00
Consensus
$18.50
High
$25.00
(16 analysts)
Share Structure
Outstanding
77,796,903.00
Float
58,689,984.00
Free Float
75.4%
Normal free float
— 75.4% of shares trade freely, ~24.6% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-2.79
Stock Price: $18.76
EPS (Diluted): -6.73
EPS (Diluted): -6.73
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.91
Stock Price: $18.76
Total Equity: $1.04B
Shares: 76,753,000
Total Equity: $1.04B
Shares: 76,753,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-11.28
Market Cap: $1.46B
Total Debt: $1.86B
Cash: $235.05M
EBITDA: -$326.20M
Total Debt: $1.86B
Cash: $235.05M
EBITDA: -$326.20M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$2.8B
Market Cap: $1.46B
Total Debt: $1.86B
Cash: $235.05M
Total Debt: $1.86B
Cash: $235.05M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.58
Stock Price: $18.76
Revenue: $1.64B
Shares: 76,753,000
Revenue: $1.64B
Shares: 76,753,000
EV/Sales (Total value vs revenue — works when P/E can't)
API1.68
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
51.7%
Gross Profit: $845.23M
Revenue: $1.64B
Revenue: $1.64B
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
4.2%
Operating Income: $68.32M
Revenue: $1.64B
Revenue: $1.64B
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-31.6%
Net Income: -$516.47M
Revenue: $1.64B
Revenue: $1.64B
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-47.6%
Net Income: -$516.47M
Total Equity: $1.04B
Total Equity: $1.04B
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
3.5%
Operating Income: $68.32M
Tax Rate: 8.3%
Equity: $1.04B
Total Debt: $1.86B
Cash: $235.05M
Tax Rate: 8.3%
Equity: $1.04B
Total Debt: $1.86B
Cash: $235.05M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.54
Current Assets: $1.16B
Current Liabilities: $455.98M
Current Liabilities: $455.98M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
1.78
Short-Term Debt: $126.55M
Long-Term Debt: $1.73B
Total Debt: $1.86B
Total Equity: $1.04B
Long-Term Debt: $1.73B
Total Debt: $1.86B
Total Equity: $1.04B
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$21.31
Revenue: $1.64B
Shares: 76,753,000
Shares: 76,753,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$13.60
Total Equity: $1.04B
Shares: 76,753,000
Shares: 76,753,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.59
Operating CF: $50.38M
CapEx: -$95.64M
Shares: 76,753,000
CapEx: -$95.64M
Shares: 76,753,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $18.76
Stock Price: $18.76
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$516.47M
Net Income: -$516.47M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares IART against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 3:17pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.5B | $1.6B | $1.5B | $1.6B | $1.6B |
| Cost of Revenue | $597.8M | $587.4M | $656.8M | $728.5M | $790.0M |
| Gross Profit | $944.6M | $970.3M | $884.7M | $882.1M | $845.2M |
| Operating Expenses | $747.4M | $731.4M | $773.2M | $853.7M | $776.9M |
| Operating Income | $197.2M | $238.9M | $111.5M | $28.4M | $68.3M |
| Net Income | $169.1M | $180.6M | $67.7M | -$6.9M | -$516.5M |
| EBITDA | $366.3M | $384.6M | $256.0M | $193.3M | -$326.2M |
| EPS | $2.00 | $2.18 | $0.87 | $-0.09 | $-6.73 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 3:17pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $513.4M | $456.7M | $276.4M | $246.4M | $235.0M |
| Total Current Assets | $1.2B | $1.2B | $1.1B | $1.1B | $1.2B |
| Total Assets | $3.8B | $3.9B | $3.8B | $4.0B | $3.6B |
| Current Liabilities | $340.0M | $320.9M | $307.0M | $922.1M | $456.0M |
| Long-Term Debt | $1.5B | $1.4B | $1.5B | $1.2B | $1.7B |
| Total Liabilities | $2.1B | $2.1B | $2.2B | $2.5B | $2.6B |
| Total Equity | $1.7B | $1.8B | $1.6B | $1.5B | $1.0B |
| Retained Earnings | $698.6M | $879.1M | $946.9M | $939.9M | $423.4M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 3:17pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $312.4M | $264.5M | $140.0M | $129.4M | $50.4M |
| Capital Expenditure | -$48.1M | -$47.1M | -$66.9M | -$104.4M | -$95.6M |
| Free Cash Flow | $264.3M | $217.4M | $73.1M | $25.0M | -$45.3M |
| Acquisitions (net) | -$113.4M | -$27.5M | $0 | -$277.8M | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | -$125.0M | -$275.0M | -$52.5M | $-221,000 |
| Net Change in Cash | $43.3M | -$56.8M | -$180.3M | -$30.0M | -$11.3M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 9:04am (just now)| Metric | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Revenue |
$1.6B $1.6B – $1.7B
|
$1.7B $1.7B – $1.7B
|
$1.7B $1.7B – $1.7B
|
$1.8B $1.8B – $1.8B
|
| EBITDA |
$186.2M $184.6M – $188.5M
|
$191.4M $190.2M – $192.5M
|
$197.7M $196.6M – $198.9M
|
$204.2M $204.2M – $204.2M
|
| Net Income |
$169.0M $167.4M – $170.5M
|
$187.3M $185.8M – $188.9M
|
$200.2M $194.0M – $206.4M
|
$219.7M $182.2M – $257.2M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 3:17pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +1.0% | -1.0% | +4.5% | +1.5% |
| Gross Profit Growth | +2.7% | -8.8% | -0.3% | -4.2% |
| Operating Income Growth | +21.1% | -53.3% | -74.5% | +140.5% |
| Net Income Growth | +6.8% | -62.5% | -110.3% | -7,337.7% |
| EBITDA Growth | +5.0% | -33.4% | -24.5% | -268.8% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-07 | HILL BARBARA B | A-Award | 17,700.00 | $0.00 | $0 |
| 2026-05-07 | HILL BARBARA B | A-Award | 6,638.00 | $0.00 | $0 |
| 2026-05-09 | BRADLEY KEITH | F-InKind | 882.00 | $13.92 | $12,277 |
| 2026-05-07 | BRADLEY KEITH | A-Award | 17,700.00 | $0.00 | $0 |
| 2026-05-07 | Clay Shaundra | A-Award | 17,700.00 | $0.00 | $0 |
| 2026-05-07 | GRAVES JEFFREY A | A-Award | 17,700.00 | $0.00 | $0 |
| 2026-05-07 | Lo Renee Wonlai | A-Award | 17,700.00 | $0.00 | $0 |
| 2026-05-07 | SCHADE CHRISTIAN S | A-Award | 17,700.00 | $0.00 | $0 |
| 2026-03-11 | Singh Harvinder | A-Award | 60,865.00 | $0.00 | $0 |
| 2026-03-11 | Singh Harvinder | M-Exempt | 18,922.00 | $0.00 | $0 |
| 2026-03-11 | Singh Harvinder | F-InKind | 5,190.00 | $9.61 | $49,876 |
| 2026-03-10 | Singh Harvinder | M-Exempt | 1,216.00 | $0.00 | $0 |
| 2026-03-10 | Singh Harvinder | F-InKind | 601.00 | $9.55 | $5,740 |
| 2026-03-11 | Singh Harvinder | F-InKind | 861.00 | $9.61 | $8,274 |
| 2026-03-10 | Singh Harvinder | M-Exempt | 1,216.00 | $0.00 | $0 |
| 2026-03-11 | Singh Harvinder | M-Exempt | 2,356.00 | $0.00 | $0 |
| 2026-03-11 | Singh Harvinder | M-Exempt | 16,566.00 | $0.00 | $0 |
| 2026-03-11 | McBreen Michael J. | A-Award | 92,108.00 | $0.00 | $0 |
| 2026-03-10 | McBreen Michael J. | F-InKind | 2,354.00 | $9.55 | $22,481 |
| 2026-03-11 | McBreen Michael J. | F-InKind | 7,247.00 | $9.61 | $69,644 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for IART — it's generated by the pipeline (
market-narrative step).
No community reviews yet for IART.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30